Patients with GIST with KIT or PDGFRA mutations and sensitive to the tyrosine kinase inhibitor (TKI) at high risk of relapse have improved survival with adjuvant imatinib treatment. The gene discussed is KIT; the disease is gastrointestinal stromal tumor.